[go: up one dir, main page]

MX2017010552A - Receptor antigenico quimerico. - Google Patents

Receptor antigenico quimerico.

Info

Publication number
MX2017010552A
MX2017010552A MX2017010552A MX2017010552A MX2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptor
car
coiled
association
Prior art date
Application number
MX2017010552A
Other languages
English (en)
Other versions
MX371384B (es
Inventor
Cordoba Shaun
PULÉ Martin
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of MX2017010552A publication Critical patent/MX2017010552A/es
Publication of MX371384B publication Critical patent/MX371384B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona un polipéptido formador de receptor antigénico quimérico (CAR) que comprende: (i) un dominio de unión a antígenos; (ii) un dominio espaciador de hélice superenrollada; (iii) un dominio transmembranal; y (iv) un endodominio. La invención también proporciona un CAR multimérico formado por la asociación de una pluralidad de polipéptidos formadores de CAR en virtud de la asociación de sus dominios espaciadores de hélice superenrollada.
MX2017010552A 2015-03-23 2016-03-22 Receptor antigenico quimerico. MX371384B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504840.8A GB201504840D0 (en) 2015-03-23 2015-03-23 Chimeric antigen receptor
PCT/GB2016/050795 WO2016151315A1 (en) 2015-03-23 2016-03-22 Chimeric antigen receptor

Publications (2)

Publication Number Publication Date
MX2017010552A true MX2017010552A (es) 2018-03-14
MX371384B MX371384B (es) 2020-01-28

Family

ID=53052211

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010552A MX371384B (es) 2015-03-23 2016-03-22 Receptor antigenico quimerico.

Country Status (21)

Country Link
US (1) US11058722B2 (es)
EP (1) EP3274366B8 (es)
JP (3) JP6675417B2 (es)
KR (1) KR102174280B1 (es)
CN (1) CN107406518B (es)
AU (1) AU2016238583B2 (es)
BR (1) BR112017018252A2 (es)
CA (1) CA2978852C (es)
CL (1) CL2017002413A1 (es)
DK (1) DK3274366T3 (es)
ES (1) ES2773527T3 (es)
GB (1) GB201504840D0 (es)
HU (1) HUE047929T2 (es)
IL (1) IL254254B (es)
MX (1) MX371384B (es)
PL (1) PL3274366T3 (es)
PT (1) PT3274366T (es)
RU (1) RU2752880C2 (es)
SG (1) SG11201706940QA (es)
WO (1) WO2016151315A1 (es)
ZA (1) ZA201705682B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948544A4 (en) 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
US11885807B2 (en) 2014-03-05 2024-01-30 Autolus Limited Method for depleting malignant T-cells
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201501936D0 (en) * 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
EA202090931A3 (ru) 2015-05-18 2020-10-30 Тср2 Терапьютикс Инк. Композиции и способы перепрограммирования tcr с помощью гибридных белков
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CN112280796A (zh) 2016-10-07 2021-01-29 T细胞受体治疗公司 使用融合蛋白进行t细胞受体重编程的组合物和方法
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
US20200181225A1 (en) * 2017-03-29 2020-06-11 Sunnybrook Research Institute Engineered t-cell modulating molecules and methods of using same
AU2018367896B2 (en) 2017-05-12 2023-06-01 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
CN111164203A (zh) * 2017-08-02 2020-05-15 奥托路斯有限公司 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞
EP3704150A1 (en) * 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG The compbody - a multivalent target binder
GB201801831D0 (en) * 2018-02-05 2018-03-21 Autolus Ltd Chimeric receptor
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CA3099831A1 (en) 2018-05-15 2019-11-21 Autolus Limited Chimeric antigen receptor
CN112930186A (zh) * 2018-08-16 2021-06-08 纪念斯隆-凯特琳癌症中心 基于亮氨酸拉链的组合物和使用方法
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
PT3856775T (pt) 2018-09-27 2025-01-31 Autolus Ltd Recetor antigénico quimérico
EP3860643A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3860642A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
GB201817822D0 (en) 2018-10-31 2018-12-19 Autolus Ltd Binding domain
CN113891718B (zh) * 2019-02-21 2025-01-28 杭州天康麦生物技术有限公司 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3962535A1 (en) 2019-04-30 2022-03-09 CRISPR Therapeutics AG Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
GB201919017D0 (en) 2019-12-20 2020-02-05 Autolus Ltd Cell
CN111234033B (zh) * 2020-01-21 2021-05-11 南京北恒生物科技有限公司 多链嵌合抗原受体及其用途
GB202004263D0 (en) 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202017649D0 (en) 2020-11-09 2020-12-23 Autolus Ltd Polypeptide
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
GB202115329D0 (en) * 2021-10-25 2021-12-08 Autolus Ltd Chimeric cytokine receptor
WO2024019961A1 (en) * 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cd2 recruiting chimeric antigen receptors and fusion proteins
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
KR101156085B1 (ko) * 2010-01-29 2012-06-20 국립암센터 ４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도
US10745467B2 (en) * 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US9175308B2 (en) * 2011-10-07 2015-11-03 Mie University Chimeric antigen receptor
CN111676196A (zh) * 2012-05-25 2020-09-18 塞勒克提斯公司 工程化异体和免疫抑制耐受性t细胞的方法
JP6352920B2 (ja) * 2012-09-04 2018-07-04 セレクティス 多重鎖キメラ抗原受容体およびその使用
KR102332790B1 (ko) * 2013-02-15 2021-12-01 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
CN103145849B (zh) * 2013-02-18 2014-06-11 冯振卿 嵌合抗原受体及其用途
RU2729463C2 (ru) * 2013-12-20 2020-08-06 Фред Хатчинсон Кансэр Рисёч Сентер Меченые химерные эффекторные молекулы и их рецепторы
CN113307880B (zh) 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
GB201610512D0 (en) 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor

Also Published As

Publication number Publication date
JP6675417B2 (ja) 2020-04-01
DK3274366T3 (da) 2020-02-10
EP3274366B8 (en) 2020-02-12
IL254254A0 (en) 2017-10-31
US11058722B2 (en) 2021-07-13
HUE047929T2 (hu) 2020-05-28
PL3274366T3 (pl) 2020-06-15
PT3274366T (pt) 2020-01-30
JP2023021396A (ja) 2023-02-10
CN107406518B (zh) 2022-02-01
BR112017018252A2 (pt) 2018-04-10
US20180050065A1 (en) 2018-02-22
WO2016151315A1 (en) 2016-09-29
ES2773527T3 (es) 2020-07-13
RU2752880C2 (ru) 2021-08-11
MX371384B (es) 2020-01-28
ZA201705682B (en) 2018-12-19
IL254254B (en) 2021-04-29
KR102174280B1 (ko) 2020-11-04
AU2016238583B2 (en) 2020-08-13
CA2978852C (en) 2021-10-19
CN107406518A (zh) 2017-11-28
SG11201706940QA (en) 2017-09-28
KR20180009738A (ko) 2018-01-29
RU2017132978A3 (es) 2019-06-24
JP2018510639A (ja) 2018-04-19
GB201504840D0 (en) 2015-05-06
CA2978852A1 (en) 2016-09-29
EP3274366A1 (en) 2018-01-31
RU2017132978A (ru) 2019-04-08
EP3274366B1 (en) 2019-12-11
NZ735267A (en) 2021-04-30
CL2017002413A1 (es) 2018-03-16
AU2016238583A1 (en) 2017-09-28
JP2020048588A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
MX2017010552A (es) Receptor antigenico quimerico.
MX2021012720A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
MX389057B (es) Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.
MX376026B (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
EA032960B1 (ru) Антитела, содержащие химерные константные домены
MX389021B (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2016006303A (es) Celula.
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
MX2017003640A (es) Receptores antigenicos quimericos.
WO2017066481A8 (en) Chimeric antigen receptors containing a chlorotoxin domain
EA201792042A1 (ru) T-клетка, которая экспрессирует t-клеточный рецептор (tcr) гамма-дельта и химерный антигенный рецептор (car)
PH12015502572A1 (en) Chimeric fvii-xten molecules and uses thereof
NZ728674A (en) Signalling system
MX373779B (es) Receptor quimérico de antígeno anti-cd19 humanizado.
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
MX374929B (es) RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
MX352599B (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
HK1220910A1 (zh) 抗-gpiib/iiia抗體或其用途
WO2013115410A3 (en) Anti-phospholipase d4 antibody
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
BR112016022369A2 (pt) receptores quiméricos de antígeno cd33-específicos para imunoterapia contra o câncer
NZ750009A (en) Antibodies comprising chimeric constant domains
NZ758571A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
BR112016019643A2 (pt) receptores químéricos de antígeno específico de cd123 para imunoterapia anticancerígena

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: AUTOLUS LTD

Owner name: RESPIVERT LTD.

FG Grant or registration
PD Change of proprietorship

Owner name: AUTOLUS LIMITED